Filtered By:
Management: Food and Drug Administration (FDA)
Therapy: Corticosteroid Therapy

This page shows you your search results in order of date.

Order by Relevance | Date

Total 3 results found since Jan 2013.

What to Know About Severe Asthma in Kids
Asthma isn’t always a quick and easy diagnosis in children. According to a 2014 task force assembled by the American Thoracic Society and the European Respiratory Society, pediatric severe asthma can be diagnosed if a child’s symptoms require treatment with high-dose inhaled corticosteroids plus a second “controller” medication for a full year, and/or systemic corticosteroids for half a year or longer. In other words, its diagnostic criteria are based on the intractability of its symptoms. “It’s definitely a limitation when you’re defining a disease state based on how much medicine...
Source: TIME: Health - October 21, 2022 Category: Consumer Health News Authors: Markham Heid Tags: Uncategorized Disease healthscienceclimate Source Type: news

FDA approves Xolair ® (omalizumab) for adults with nasal polyps
             Basel, 01 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved the company ’s supplemental Biologics License Application (sBLA) for Xolair® (omalizumab) for the add-on maintenance treatment of nasal polyps in adult patients 18 years of age and older with inadequate response to nasal corticosteroids.1 Nasal polyps can lead to a loss of smell and nasal congestion, and frequently co-occur with other respiratory conditions, such as allergies and asthma. With this approval, Xolair is now the first biologic for the treatment ...
Source: Roche Media News - December 1, 2020 Category: Pharmaceuticals Source Type: news